RNA Impact Factor

Among Biochemistry & Molecular Biology journals, RNA ranks in the top 22% by impact factor (JCR 2024). This ranking is based on our analysis of 20,449 journals in the Clarivate JCR 2024 database.

The impact factor tells you that RNA papers are cited at a moderate rate within molecular biology. The five-year JIF (4.7) running slightly below the two-year (5.0) suggests a relatively flat citation trajectory. Unlike database or methods papers that accumulate citations over time, RNA journal papers follow a more standard primary-research citation pattern.

The 12,706 total cites figure is modest, reflecting both the journal's focused scope and the relatively small size of the dedicated RNA biology community. That does not mean the journal lacks influence. In a specialist field, a well-placed paper in the dedicated community journal can have outsized practical impact even if the raw citation numbers are lower than what a broader venue would generate.

The Q1 status (rank 70 out of 319) confirms that RNA performs well within the very large Biochemistry & Molecular Biology category, even as a specialist title.

The JIF has been stable in the 4.4 to 5.1 range over five years. The slight uptick to 5.0 in 2024 is encouraging but within normal fluctuation. This is a stable, mature journal.

RNA editors evaluate papers based on contribution to RNA biology. The journal covers all aspects of RNA science:

• RNA structure and folding
• RNA processing, splicing, and editing
• mRNA translation and regulation
• Non-coding RNA biology
• RNA-protein interactions
• Ribozymes and RNA catalysis
• RNA therapeutics and technology
• Computational RNA biology

The editorial bar is solid but more accessible than flagships like Molecular Cell. Papers need to advance RNA biology in a meaningful way, but they do not need to have the broad conceptual reach that the top-tier journals demand. Technically rigorous work with clear contribution to RNA understanding fits well.

Submit if:

• the paper is primarily about RNA biology in one of the journal's core areas
• the audience is the specialist RNA research community
• Cold Spring Harbor tradition and RNA-specific branding matter for your visibility
• the work advances RNA biology but may be too specialized for broader venues
• you want a well-respected specialist journal with reasonable turnaround

Think twice if:

• Nucleic Acids Research would give the work substantially broader visibility
• the RNA component is secondary to a larger biological finding
• Molecular Cell, Cell Reports, or another broader journal is a realistic target
• the work has therapeutic or translational implications that a disease-focused journal would reward
• the paper describes a tool or database that would fit NAR's Database issue better

The RNA field has grown substantially in recent years, driven by mRNA therapeutics, CRISPR, and expanding non-coding RNA biology. That growth has created more publishing options:

• Nucleic Acids Research (IF 13.1): the broadest nucleic acid journal, covering both DNA and RNA
• RNA (IF 5.0): the dedicated specialist journal
• RNA Biology (IF ~4): another RNA specialist journal with broader scope
• Molecular Cell (IF 16.6): for RNA papers with exceptional mechanistic breadth
• Nature Structural & Molecular Biology (IF 10.1): for RNA structural biology with mechanistic insight

For RNA researchers, the choice depends on how broad the biological consequence is and whether the paper benefits from specialist or generalist audiences.

In our pre-submission review work on manuscripts targeting RNA, three patterns account for most of the desk rejections we see.

Papers that describe RNA involvement without RNA as the central mechanistic story. RNA journals attract authors whose primary investigation is a gene, a pathway, or a disease, with RNA-level analysis as supporting data. A paper that profiles differential expression patterns across conditions, then concludes that "these results suggest altered RNA regulation," is not an RNA biology paper in the journal's terms. RNA wants work where the RNA-level mechanism (processing, modification, structure, interaction, regulation) is the primary subject of investigation. Manuscripts where RNA is the assay rather than the protagonist get desk-rejected quickly. The central question the paper answers needs to be about how an RNA does something, not about what is changed or correlated in a disease model.

Large-scale RNA profiling studies that map changes without identifying a mechanism. The journal's scope describes its standard as "significant experimental and computational results and emerging concepts in ribonucleic acid research." Significance in RNA biology terms means advancing understanding of how RNA functions, not cataloguing what changes across conditions. A paper that performs RNA-seq across patient samples or developmental stages and identifies differentially expressed or spliced transcripts is valuable to biology, but it is not an RNA biology paper in the journal's sense unless it explains a mechanism of RNA regulation, processing, or function. Computational RNA biology is explicitly within scope (the journal covers bioinformatics and genomics) but the contribution needs to be an insight about RNA behavior, not only a dataset or a pattern. Studies that use RNA-seq as a measurement technology to answer questions about development, disease, or cell biology belong in journals that own those subjects.

Methods, tools, and database papers where RNA is the input rather than the subject. The RNA Society describes the journal's mission as "RNA-centered science", a phrase that distinguishes work where RNA biology is the object of inquiry from work where RNA data is input to a general-purpose method. Nucleic Acids Research explicitly publishes an annual Database Issue and welcomes methods papers covering nucleic acid research broadly. A new alignment algorithm, a splicing prediction tool, or an RNA modification annotation database fits that context more naturally than RNA journal, even if the tool is validated entirely on RNA sequences. The journal's scope statement covers bioinformatics, but the editorial question is whether the paper's core contribution is something specific to how RNA molecules behave, fold, or function, or whether it is a general method that happens to have been tested on RNA. If the paper's main claim survives unchanged with DNA or protein data substituted, the biological question is not about RNA, and the journal is not the right venue.

• Whether the RNA biology community will recognize the contribution
• How the Cold Spring Harbor Press brand is perceived in your subfield
• Whether a broader venue would give the paper more career value
• How long the review process will take
• Whether RNA Biology or another RNA-adjacent journal is a better fit

RNA's 5.0 is one of the clearer examples of a journal whose value is more community-specific than the headline metric suggests. The journal is not trying to be a broad molecular-biology prestige vehicle. It is the specialist home for RNA biology, and that means the right submission decision often turns on audience concentration rather than on raw citation reach. A paper in RNA may have fewer average citations than one in Nucleic Acids Research or Molecular Cell, but it can still land more directly with the researchers who actually build on RNA-focused work.

That is why the page should guide searchers toward readership logic instead of number worship. RNA makes the most sense when the main claim is squarely about RNA biology, mechanism, or regulation and the specialist audience is the advantage, not the compromise. If the paper's real value is broader genomics infrastructure, a structural biology leap, or a wide mechanistic biology story, a higher-citation venue may be the cleaner choice. But when the whole point is that the work belongs inside the RNA field's ongoing conversation, the dedicated journal identity matters more than chasing a bigger JIF elsewhere.

Use the trend as a reminder that journal choice is partly about where the paper will be understood fastest. RNA works best when the manuscript gains value from specialist credibility, field memory, and readers who care specifically about RNA rather than molecular biology in the abstract.

Last verified: March 2026 against Clarivate JCR 2024 data.